Better Therapeutics (NASDAQ:BTTX) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 24.07 percent increase over losses of $(0.54) per share from the same period last year.
Baird Downgrades Signify Health to Neutral, Lowers Price Target to $24
Baird analyst Vikram Kesavabhotla downgrades Signify Health (NYSE:SGFY) from Outperform to Neutral and lowers the price target from $30 to $24.
